Treat Frontotemporal Dementia (FTD) Fund

Up to $2,000,000 based on stage and scope of the trial. For studies requiring additional support, co-funding from other funding agencies or investors is encouraged. Payment structure will be negotiated and based on milestone achievements and patient enrollment.

Eligibility:

Funding is open to researchers and clinicians worldwide at:

  • Academic medical centers, universities or non-profits. Industry partnerships are encouraged.
  • Biotechnology companies. Funding is provided through mission-related investments that require return on investment based upon scientific and/or business milestones. Existing companies and new startups are eligible.

Applicants will first submit a letter of intent (LOI) that includes brief information about the proposed mechanism or mode of action, the drug, supporting data, biomarkers and proposed clinical trial features. The top LOIs will be invited to submit a full proposal that includes a clinical trial protocol, budget, team biosketches and business documents, if applicable. Applications will be reviewed confidentially by a panel of FTD experts. Applicants may expect to receive recommended revisions to their workplan or clinical trial design as part of the review process. In some circumstances, applicants may be offered access to a consultant with industry experience.

Deadline:

Letter of Intent: February 5th
Full Proposal: March 19th

Website: Treat FTD Fund

SFU Signature Sheet and Application forms due to ORS 3 days before application deadline. 

 

Upcoming Deadlines

External
Internal
March 19, 2021March 19, 2021 Verified Date
March 16, 2021 Mar. 16, 2021 March 16, 2021 16:00:00 March 16, 2021 16:00:00 America/Vancouver Application Deadline: Treat Frontotemporal Dementia (FTD) Fund The Alzheimer's Drug Discovery Foundation (ADDF) and the Association for Frontotemporal Degeneration (AFTD) launched the Treat FTD Fund to help address these challenges, build on emerging scientific understanding of biological mechanisms underlying FTD, provide critical funding for early-stage clinical trials and stimulate the field to develop new therapies for FTD disorders. .
February 05, 2021February 05, 2021 Verified Date
16:00:00 16:00:00 America/Vancouver Application Deadline: Treat Frontotemporal Dementia (FTD) Fund The Alzheimer's Drug Discovery Foundation (ADDF) and the Association for Frontotemporal Degeneration (AFTD) launched the Treat FTD Fund to help address these challenges, build on emerging scientific understanding of biological mechanisms underlying FTD, provide critical funding for early-stage clinical trials and stimulate the field to develop new therapies for FTD disorders. .

x